Search results
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Benzinga via AOL· 3 days agoThursday, Verastem Oncology (NASDAQ:VSTM) announced the initial interim safety and efficacy results...
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies | JD...
JD Supra· 4 days agoIts decision underscores the strategic advantage of employing means-plus-function limitations in cases where genus claims are not practicable or otherwise subject to attack under the Supreme ...
Shifting Antitrust Scrutiny Means Freshening Compliance Policies
Bloomberg Law· 6 days agoThis includes the FTC reviving a “conglomerate” theory of competitive harm in its challenge to Amgen Inc.’s acquisition of Horizon Therapeutics or its focus ...
Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More
WJET - WFXP Erie· 3 days agoUSA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual...
Weight-Loss Upstart Viking Needs a Deal to Vie With Lilly and Novo
Bloomberg via Yahoo Finance· 5 days ago(Bloomberg) -- Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking...
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like...
Benzinga· 6 days agoRoundhill Investments launched a new exchange-traded fund (ETF) Tuesday. What Happened: The...
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% By Investing.com
Investing.com· 5 days agoU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51%
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.51% By Investing.com
Investing.com· 5 days agoU.S. shares lower at close of trade; Dow Jones Industrial Average down 0.51%
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Benzinga· 3 days agoVerastem Oncology has established clinical collaborations with Amgen Inc AMGN and Bristol-Myers...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days agoCHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained